Integrase inhibitor-based treatment in clinical practice by Cenderello, G et al.
POSTER PRESENTATION Open Access
Integrase inhibitor-based treatment in clinical
practice
G Cenderello
*, R Piscopo, M Feasi, G Penco, N Bobbio, G Cassola
From Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010
Background
Raltegravir(RAL) is a the first compound of a novel
class: integrase inhibitors. Aim of our study was to eval-
uate efficacy and safety of RAL based regimen.
Materials and methods
We proceeded to retrospective analysis from patients
(pts) referring to our service. We searched our databases
for epidemiological, clinical, immunological and virologi-
cal issues. Moreover we recorded HCV and HBV status.
We focused our attention on the reason of ARV switch-
ing , duration of ARV before RAL introduction, immu-
nological gain, virological suppression and tolerability of
the prescribed regimen. We followed side effects in
order to define safety of prescribed regimen.
Results
We enrolled 70 pts. (male 53:female 17), according to
CDC 1993 they were classified as A(12); B(32);C(26).
Median age was 49 years, 42 pts were HCV-positive and
only 4 presented an active HBV coinfection. Risk factors
for HIV infection resulted: injective drug abuse(33)
homosexual(20) and heterosexual(17)exposition. They
were switched to RAL therapy for drug resistance(39)
(DRR); regimen simplification(7) or drug toxicity (24).
Most of patients presented multiple drug failures to
ARV therapy (almost two different classes resistance).
Median follow up was with RAL is 9 months and med-
ian extent of ARV before RAL was 9 years. Among
DRR. 29 were coming from a PI failure whereas 9 from
NNRTI based regimen and one from 3TC monotherapy.
The most represented drug associated in new ARV regi-
men was DRV/rtv (42) followed by etravirine(12) and
maraviroc (10).
We collected data of immune and virological response
after 3 and 6 months, so at 6 months 59 pts. (84.3%;
71.8 % in DRR) presented undetectable(<20) viral load
and a medium CD4 gain of 89 cc/ml(90 cc/ml in DRR).
No relevant side effects were observed.
Conclusions
Pts. treated with RAL based therapy presented a good
outcome, most of them achieve (after 6 months) virolo-
gical suppression and immunological recovery. In our
case list, darunavir/rtv and RAL obtained the best
results with no relevant side effects. So more studies are
n e e d e dt oc o n f i r mt h a tR A Lb a s e dA R Vc o u l db ev e r y
efficacious and safe even in long term follow up period.
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